S&P 500

5.277,51

0,80%

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

MOLN

Molecular Partners (MOLN)

Molecular Partners AG

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MOLN

1 2 3 4 5 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
01/06/2024	14h00	GlobeNewswire Inc.	Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024	NASDAQ:MOLN	Molecular Partners AG
17/05/2024	12h25	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:MOLN	Molecular Partners AG
17/05/2024	12h25	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:MOLN	Molecular Partners AG
17/05/2024	12h25	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:MOLN	Molecular Partners AG
17/05/2024	12h25	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:MOLN	Molecular Partners AG
16/05/2024	22h00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
16/05/2024	22h00	GlobeNewswire Inc.	Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program	NASDAQ:MOLN	Molecular Partners AG
29/04/2024	17h00	GlobeNewswire Inc.	Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action	NASDAQ:MOLN	Molecular Partners AG
19/04/2024	17h12	GlobeNewswire Inc.	Life Science Cares Launches in Switzerland	NASDAQ:MOLN	Molecular Partners AG
17/04/2024	17h12	GlobeNewswire Inc.	Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting	NASDAQ:MOLN	Molecular Partners AG
26/03/2024	14h26	GlobeNewswire Inc.	Molecular Partners Publishes Invitation to Annual General Meeting 2024	NASDAQ:MOLN	Molecular Partners AG
14/03/2024	21h00	GlobeNewswire Inc.	Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023	NASDAQ:MOLN	Molecular Partners AG
01/03/2024	22h00	GlobeNewswire Inc.	Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations	NASDAQ:MOLN	Molecular Partners AG
08/01/2024	18h33	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
07/01/2024	22h00	GlobeNewswire Inc.	Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:MOLN	Molecular Partners AG
05/01/2024	22h00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
05/01/2024	22h00	GlobeNewswire Inc.	Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies	NASDAQ:MOLN	Molecular Partners AG
14/12/2023	07h00	GlobeNewswire Inc.	Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences	NASDAQ:MOLN	Molecular Partners AG
10/12/2023	18h00	GlobeNewswire Inc.	Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting	NASDAQ:MOLN	Molecular Partners AG
14/11/2023	07h00	GlobeNewswire Inc.	Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)	NASDAQ:MOLN	Molecular Partners AG
03/11/2023	17h00	GlobeNewswire Inc.	Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting	NASDAQ:MOLN	Molecular Partners AG
02/11/2023	11h01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
02/11/2023	07h00	GlobeNewswire Inc.	Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition	NASDAQ:MOLN	Molecular Partners AG
01/11/2023	07h00	GlobeNewswire Inc.	Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit	NASDAQ:MOLN	Molecular Partners AG
26/10/2023	22h00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
26/10/2023	22h00	GlobeNewswire Inc.	Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio	NASDAQ:MOLN	Molecular Partners AG
13/09/2023	07h00	GlobeNewswire Inc.	Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting	NASDAQ:MOLN	Molecular Partners AG
24/08/2023	22h02	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
24/08/2023	22h00	GlobeNewswire Inc.	Molecular Partners Reports H1 2023 Corporate Highlights and Financials	NASDAQ:MOLN	Molecular Partners AG
28/06/2023	14h35	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:MOLN	Molecular Partners AG